Human Papillomavirus Hpv Articles & Analysis
51 news found
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. Oncovita and the Institut Pasteur have already been working together for several years on the construction and development of ...
ByOncoVITA
Airfinity announces today the launch of Airfinity IDA (Infectious Disease Analytics) 360, a new platform that will provide a comprehensive overview of vaccine and therapeutics candidates across the full infectious disease landscape. Airfinity IDA 360, a first-of-its-kind product in the health analytics market, will be a centralised source of competitive intelligence, providing clear and near ...
Viennese biotechnology company BlueSky Immunotherapies GmbH (Ltd.) has completed the second cohort of its phase 1 clinical trial against HPV 16. The results: Intradermal administration has been confirmed to be safe and well tolerated. Preliminary indications of efficacy were observed. Their proprietary innovative delNS technology for interferon-inducing viral vectors is a next-generation ...
BOC Sciences has been constantly enriching its peptide product library for years. Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem According to data from the WHO, a large number of adults are having diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. The absolute lack of insulin, due to destruction of the ...
Amerigo Scientific provides high-quality and cost-effective medical device products worldwide to advance human health and address health emergencies. Nowadays human papillomavirus (HPV) infection has been recognized as the prerequisite for most anogenital malignancies accounting for more than 90% of cervical and anal cancers, ...
(NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive Phase 1 results from its HB-200 program evaluating single-vector HB-201 and alternating 2-vector HB-202/HB-201 in advanced Human Papillomavirus 16-positive (HPV16+) head and neck cancer patients. ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The ...
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase 2 dose for alternating 2-vector HB-202/HB-201 and Phase 2 development plans in head and neck cancers HOOKIPA ...
Virusight Diagnostic, a world leader in combining artificial intelligence software and spectral technology today announced the results of a major clinical study that found its ultra-rapid, point of care Pathogens Diagnostic solution consistently delivers 96.3% accuracy when compared to the gold standard RT-PCR. The study was conducted by the Department of Science and Technology, University of ...
GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert ...
Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor control Preclinical data also expand evidence on arenaviral immunotherapy targeting tumor self-antigens, reinforcing scientific approach for HB-300 program in prostate cancer Poster presentations at AACR underscore the versatility of ...
DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the upcoming oral presentation of the discovery and initial clinical utility of a novel signature that identifies patients with head and neck squamous cell carcinoma (HNSCC) that may benefit from treatment beyond typical surgical ...
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will participate in a reside chat and 1x1 investor meetings at Oppenheimer's 32nd Annual Healthcare Conference on Tuesday, March ...
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01614-4 Primary HPV screening has doubled the number of colposcopy referrals because of direct referral of HPV-positive women with ASC-US/ LSIL cytology. This study evaluated the CIN3+ risks and colposcopy referrals by QIAsure Methylation Test analysis HPV16/18 genotyping HPV16/18/31/33/45 genotyping in HPV-positive women ...
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases, today reported financial results for the quarter and year ended December 31, 2021. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to ...
INOVIO (NASDAQ: INO) announced today that fourth quarter 2021 financial results will be released after the market close on March 1, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. A live and archived version of the audio presentation will be available online at ...
Ficlatuzumab is AVEO’s investigational potent humanized immunoglobulin G1 monoclonal antibody that targets hepatocyte growth factor. ...
INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL), including a one-year follow-up of efficacy and safety ...
The virtual 34th International Papillomavirus Conference took place last week, from November 15-19. The conference’s theme this year was: ‘Research and education for HPV elimination’. ...
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced the company is rapidly moving to evaluate its COVID-19 DNA vaccine candidates INO-4800 and INO-4802 against the emerging B.1.1.529 (Omicron) variant of concern. Concurrently, INOVIO ...